Martin Everett

Martin Everett is an accomplished scientific leader with extensive experience in the pharmaceutical and biotechnology sectors. Currently serving as Chief Scientific Officer at AUROBAC THERAPEUTICS since February 2023, Martin previously held the same title at ANTABIO SAS from December 2012 to February 2023, where the focus was on developing innovative antibacterials. Prior to this, Martin was Head of Research at MerLion Pharmaceuticals GmbH, leading natural products research for various industries from June 2005 to November 2012. Martin's career began at GSK, where responsibilities included Group Leader Screening Sciences and Senior Research Scientist from 1996 to 2005, primarily in anti-tubercular programs. Martin's academic foundation includes a PhD in Molecular Genetics of Beta-lactamases from the University of Bristol and a BSc Hons in Microbiology from Swansea University.